Home » Business, Financial

BioMarin Pharmaceutical (NASDAQ:BMRN) & DNDN Have A “Buy” And “Hold” Rating, Respectively: Consensus View

Written by on September 23, 2013

On Friday, ARN reported that in a research note analysts at Wedbush reiterated its hold rating on BioMarin Pharmaceutical (NASDAQ:BMRN)’s stock. Currently, they have $88.00 price target on the stock. Wedbush’s price objective indicates a potential rise of 14.36% from the stock’s earlier close.

Recently, BioMarin Pharmaceutical (NASDAQ:BMRN)’s stock has been weighed by a number of other analysts. On Wednesday, in a research note to investors, analysts at RBC Capital maintained a “buy” rating on company’s shares. Now, they have a $77.00 price objective on the stock. Separately, on Wednesday, in a research note to investors, analysts at William Blair maintained a “hold” rating on company’s shares. Now, they have a $88.00 price objective on the stock. Finally, on Wednesday, in a research note to investors, analysts at Stifel Nicolaus downgraded the company’s stock from a “buy” to a “hold” rating. Now, they set a $70.00 price objective on the stock. Eight investment analysts have given a hold rating and thirteen have rated as buy. The company has an average rating of “Buy” and an average price objective of $72.68.

TheFlyOnTheWall.com reported that in a research note issued to investors on Wednesday, Maxim Group upgraded the Dendreon Corp. (NASDAQ:DNDN)’s shares to a hold rating from a sell rating. The analysts called the move a valuation call.

Recently, Dendreon Corp. (NASDAQ:DNDN)’s stock has been commented by a number of other analysts. On Tuesday, in a research note to investors, analysts at Needham & Company maintained a positive rating on company’s shares. Separately, in a research note to investors on Monday, September 9th, analysts at R. F. Lafferty started coverage on company’s shares. They set $8.00 price objective on the stock, rating it as a buy. Finally, in a research note to investors on Wednesday, August 28th, analysts at RBC Capital cut their price target on company’s shares from $5.00 to $3.00. Now, they set a sell rating on the stock. Nine research analysts have given a sell rating to the stock, eight have rated the stock as hold and four have issued a buy rating to the company’s stock.  Currently, the stock has an average rating of Hold and a consensus price objective of $5.02.

Tags: , , , , ,

Leave a comment

Add your comment below, or trackback from your own site. You can also Comments Feed via RSS.

Be nice. Keep it clean. Stay on topic. No spam.

You can use these tags:
<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>